SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,294,163 | -7.8% | 46,941 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $1,404,222 | -16.3% | 46,714 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $1,677,340 | +1.5% | 46,297 | -0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,652,128 | +5.4% | 46,317 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,567,830 | +6.0% | 46,317 | -9.4% | 0.00% | -50.0% |
| Q2 2022 | $1,479,000 | -11.7% | 51,143 | -1.4% | 0.00% | +33.3% |
| Q1 2022 | $1,675,000 | +11.5% | 51,855 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $1,502,000 | +54.5% | 51,507 | +41.3% | 0.00% | +50.0% |
| Q3 2021 | $972,000 | -13.4% | 36,460 | -0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,123,000 | +12.0% | 36,476 | -4.8% | 0.00% | 0.0% |
| Q1 2021 | $1,003,000 | +27.1% | 38,329 | +22.2% | 0.00% | 0.0% |
| Q4 2020 | $789,000 | +40.9% | 31,370 | +16.8% | 0.00% | +100.0% |
| Q3 2020 | $560,000 | -43.3% | 26,869 | -35.3% | 0.00% | -50.0% |
| Q2 2020 | $987,000 | +11.7% | 41,551 | -15.4% | 0.00% | 0.0% |
| Q1 2020 | $884,000 | -22.9% | 49,131 | +1.6% | 0.00% | 0.0% |
| Q4 2019 | $1,147,000 | -85.3% | 48,368 | -83.0% | 0.00% | -88.2% |
| Q3 2019 | $7,813,000 | -32.9% | 284,310 | -19.2% | 0.02% | -32.0% |
| Q2 2019 | $11,646,000 | -34.0% | 351,935 | -30.1% | 0.02% | -37.5% |
| Q1 2019 | $17,654,000 | -20.0% | 503,832 | -24.1% | 0.04% | -25.9% |
| Q4 2018 | $22,057,000 | -33.7% | 663,951 | +0.5% | 0.05% | -20.6% |
| Q3 2018 | $33,251,000 | -5.1% | 660,406 | +12.8% | 0.07% | -9.3% |
| Q2 2018 | $35,031,000 | +1250.5% | 585,319 | +933.5% | 0.08% | +1150.0% |
| Q1 2018 | $2,594,000 | +14.9% | 56,634 | 0.0% | 0.01% | +20.0% |
| Q4 2017 | $2,257,000 | -13.7% | 56,634 | -13.3% | 0.01% | -16.7% |
| Q3 2017 | $2,614,000 | -14.9% | 65,356 | -8.3% | 0.01% | -14.3% |
| Q2 2017 | $3,073,000 | +10.1% | 71,298 | -20.1% | 0.01% | +16.7% |
| Q1 2017 | $2,792,000 | +124.1% | 89,193 | +80.7% | 0.01% | +100.0% |
| Q4 2016 | $1,246,000 | +146.7% | 49,356 | +141.6% | 0.00% | +200.0% |
| Q3 2016 | $505,000 | +21.4% | 20,431 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $416,000 | -41.0% | 20,431 | -55.8% | 0.00% | -50.0% |
| Q1 2016 | $705,000 | +104.9% | 46,219 | +80.5% | 0.00% | +100.0% |
| Q4 2015 | $344,000 | +53.6% | 25,603 | +60.5% | 0.00% | 0.0% |
| Q3 2015 | $224,000 | -35.1% | 15,949 | -21.5% | 0.00% | 0.0% |
| Q2 2015 | $345,000 | +40.2% | 20,308 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $246,000 | +45.6% | 20,308 | 0.0% | 0.00% | – |
| Q4 2014 | $169,000 | -4.0% | 20,308 | 0.0% | 0.00% | – |
| Q3 2014 | $176,000 | -20.7% | 20,308 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $222,000 | – | 20,308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |